A pivotal, Phase 3 trial of MYK-461 in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM)

Trial Profile

A pivotal, Phase 3 trial of MYK-461 in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM)

Planning
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Mavacamten (Primary)
  • Indications Hypertrophic cardiomyopathy
  • Focus Registrational; Therapeutic Use
  • Sponsors MyoKardia
  • Most Recent Events

    • 27 Jun 2017 New trial record
    • 13 Mar 2017 According to a FORM 10-K of MyoKardia, overall duration of this trial will be approximately two years.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top